BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, April 17 /PRNewswire-FirstCall/ -- Shire plc will announce first quarter 2007 earnings on Wednesday 25 April 2007.
Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT
Live conference call for investors:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:00 BST/9:00 EDT.
Please RSVP ssalah@shire.com (T: +44-(0)1256-894-160) for this conference call.
The details of the live conference call are as follows: UK dial in 0800-953-0936 US dial in 1866-224-2972 International dial in +44-(0)-1452-568-061 Password/Conf ID 5717753#
Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for two weeks. Details are as follows: UK dial in 0800-953-1533 / 0845-245-5205 US dial in 1866-247-4222 International dial in +44-(0)1452-55-00-00 Pin code 5717753# Webcast replay www.shire.com, in the investors section For further information please contact: Investor Relations: Souheil Salah (Rest of the World) +44-1256-894-160 Heidi Wunder (North America) +1-484-595-8970 Notes to Editors SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.
Shire plc
CONTACT: For further information please contact: Investor Relations:Souheil Salah (Rest of the World), +44-1256-894-160. Heidi Wunder (NorthAmerica), +1-484-595-8970
